Alpha 1 Antitrypsin Deficiency Treatment

Global Market Trajectory & Analytics

MCP16141

EXECUTIVE ENGAGEMENTS

POOL

3682
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

662
Interactions with Platform & by Email

PARTICIPANTS

112
Unique # Participated

VALIDATIONS

32
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

159

PAGES

235

EDITION

8

PRICE

USD 4950

CODE

MCP16141


COMPETITIVE METRICS

COMPANY

D S N T

% *

Abeona Therapeutics

Login Required

AGTC

Login Required

Arrowhead Pharmaceuticals, Inc.

Login Required

AstraZeneca PLC

Login Required

Baxter International, Inc.

Login Required

Biogen, Inc.

Login Required

Boehringer Ingelheim International GmbH

Login Required

Chiesi Farmaceutici SpA

Login Required

CSL Behring

Login Required

Curaxys

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 46 COMPETITORS

Login to access data silos

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Augmentation Therapy, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bronchodilator segment is readjusted to a revised 9.4% CAGR for the next 7-year period.
The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$463.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$493.1 Million by the year 2027 trailing a CAGR of 8.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.
In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$189.6 Million in the year 2020 will reach a projected size of US$319.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$328.4 Million by the year 2027.

SELECT PLAYERS

Abeona Therapeutics Inc.; Applied Genetic Technologies Corporation; Arrowhead Pharmaceuticals Inc.; AstraZeneca PLC; Baxter International, Inc.; Biogen, Inc.; Boehringer Ingelheim International GmbH; Chiesi Farmaceutici SpA; CSL Behring; Curaxys; GlaxoSmithKline PLC; Grifols International SA; Kamada Ltd.; Pfizer, Inc.; ProBioGen AG; ProMetic Life Sciences, Inc.; Shire PLC; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» End-Use (Specialty Clinics, Hospitals, Pharmacies) » Route of Administration (Parenteral, Inhalation, Oral) » Treatment (Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, Other Treatments)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Augmentation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Bronchodilator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oxygen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
China Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
China Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
France Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
France Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027
Total Companies Profiled: 46

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com